{"analyses":[{"ciLowerLimit":"1.896","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"43.199","groupDescription":"The incidence of durable platelet response was compared by the Cochran-Mantel-Haenszel test stratified by the baseline age group. The Mantel-Haenszel common odds ratio (romiplostim vs placebo) was estimated along with its 95% confidence interval.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0018","paramType":"Odds Ratio (OR)","paramValue":"9.0497","statisticalComment":"P-value from Cochran-Mantel-Haenszel test stratified by baseline age group.","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.2","upperLimit":"31.7","value":"10.0"},{"groupId":"OG001","lowerLimit":"36.4","upperLimit":"68.0","value":"52.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"description":"A participant with durable platelet response was defined as achieving at least 6 weekly platelet counts of ≥ 50 x 10\\^9/L during the last 8 weeks of treatment (platelet counts obtained from week 18 to week 25). If a platelet count from a participant was not available (missing) in a certain week, that week was imputed as non-response for that participant. Platelet counts were not deemed as a positive response for 4 weeks after the administration of rescue medication.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received weekly subcutaneous placebo for 24 weeks.","id":"OG000","title":"Placebo"},{"description":"Participants received once weekly subcutaneous romiplostim for 24 weeks at a starting dose of 1 µg/kg; weekly dose increases continued in increments of 1 µg/kg/week to a maximum dose of 10 µg/kg in an attempt to reach a target platelet count of ≥ 50 x 10\\^9/L.","id":"OG001","title":"Romiplostim"}],"paramType":"NUMBER","populationDescription":"Efficacy analysis set (all randomized participants)","reportingStatus":"POSTED","timeFrame":"Week 18 to week 25","title":"Percentage of Participants With a Durable Platelet Response","type":"PRIMARY","unitOfMeasure":"percentage of participants"}